Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer’s Disease

The incidence of neurodegenerative diseases, such as Alzheimer’s disease (AD), is continuously growing worldwide, which leads to a heavy economic and societal burden. The lack of a safe and effective causal therapy in cognitive decline is an aggravating factor and requires investigations into the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanciu, Gabriela Dumitrita, Ababei, Daniela Carmen, Solcan, Carmen, Bild, Veronica, Ciobica, Andrei, Beschea Chiriac, Sorin-Ioan, Ciobanu, Loredana Maria, Tamba, Bogdan-Ionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674192/
https://www.ncbi.nlm.nih.gov/pubmed/38004485
http://dx.doi.org/10.3390/ph16111620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674192/
https://www.ncbi.nlm.nih.gov/pubmed/38004485
http://dx.doi.org/10.3390/ph16111620

Ejemplares similares